SCOTUS faces a new mifepristone showdown as Fifth Circuit challenges loom
Two pharma-backed cases—Danco Laboratories v. Louisiana and GenBioPro v. Louisiana—bring a new Supreme Court reckoning over mifepristone, the Fifth Circuit’s standing theory, and what relief a federal court may grant that could upend the FDA’s REMS and mail‑order access. The Court’s course may mirror its Alliance ruling, potentially preserving access while the policy framework evolves, but the decision remains uncertain amid abortion politics and jurisdiction questions.
